Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract Background Cerebral amyloid angiopathy (CAA) is closely related and coexists with Alzheimer's disease (AD) and is considered a major risk factor for the development of ARIA in patients receiving anti‐amyloid therapies. Brain magnetic resonance imaging (MRI) is the standard method for assessing the presence of CAA, but its performance has been poorly studied in this population. Our objective was to evaluate the diagnostic performance of the Boston criteria version 2.0 for the diagnosis of CAA in a cohort of individuals diagnosed with advanced AD with neuropathological confirmation. Method We included 63 individuals from the VARS cohort of the Alzheimer´s Centre Reina Sofía ‐ CIEN Foundation, a clinicopathological cohort of dementia patients, with no history of intracranial haemorrhage. All had undergone at least one antemortem MRI with T1, T2, T2 Flair and GRE sequences, and a brain autopsy with evaluation of CAA using the modified Vonsattel scale. The performance of the Boston v2.0 criteria was evaluated by comparison with neuropathologically verified CAA. Result The mean age at MRI was 84.7 ± 7 years and the median time from MRI to death was 2.5 years [0.6‐4.5]. 54 were women (86%). 46 (73%) individuals had neuropathologically confirmed CAA (i.e. moderate or severe CAA). 38 (60,3%) subjects did not meet the Boston v2.0 criteria and 45% of them had moderate or severe CAA. The sensitivity and specificity of the Boston v2.0 criteria were 40.8% [95% CI 27%‐55.8%] and 64.2% [95% CI 35.1%‐87.2%] respectively for the diagnosis of probable CAA (AUC 0.52), and 83.7% [95% CI 70.3%‐92.7%] and 35.7% [95% CI 12.8%‐64.9%] for the diagnosis of possible CAA (AUC 0.51). Conclusion The Boston v2.0 criteria have low accuracy in patients with AD dementia. New biomarkers are needed to improve the diagnosis of CAA in this population in order to improve the safety of treatment with anti‐amyloid drugs.

What this study adds

Evidence grade: Moderate

The record lists 63 participants. In 63 autopsy-confirmed dementia cases, 60.3% did not meet the Boston v2.0 criteria for cerebral amyloid angiopathy, and 45% of those had moderate or severe CAA. Reported effect size: 40.8%; 55.8%; 64.2%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ricciardi, M. E., Burgueño‐García, I., Valeriano-Lorenzo, E., Zea‐Sevilla, M. A., Valenti, M., Frades, B., et al. (2025). Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105538

Vancouver

Ricciardi ME, Burgueño‐García I, Valeriano-Lorenzo E, Zea‐Sevilla MA, Valenti M, Frades B, et al. Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105538.

BibTeX

@article{ricciardi2025-7cc0ff47,
  author  = {Ricciardi, Mario Emiliano and Burgueño‐García, Iván and Valeriano-Lorenzo, Elizabeth and Zea‐Sevilla, María Ascensión and Valenti, Meritxell and Frades, Belén and Torres, Isabel López and Anton‐Moreno, Marta and others},
  title   = {{Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_105538},
  url     = {https://doi.org/10.1002/alz70856_105538}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 63 autopsy-confirmed dementia cases, 60.3% did not meet the Boston v2.0 criteria for cerebral amyloid angiopathy, and 45% of those had moderate or severe CAA. This indicates the MRI-based criteria missed CAA in many patients, which matters for assessing ARIA risk, but the study tests diagnosis, not treatment or cure.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 36 of the 96 points it could be judged on, which is 38 of 100. Total 38 of 100.36 of the 96 points we could judge = 38 of 100

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 63 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Pascual Sanchez‐Juan holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Instituto de Salud Carlos III: institution h-index 649 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 36 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100.
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →